Keyword: Flexion Therapeutics
Zilretta has several things going for it. It's not an opioid painkiller and it lasts longer than rival shots. So why isn't its launch speeding ahead?
Here are some other pharma industry stories we're following today.
Flexion's raring to launch its knee injection Zilretta, and it's floating a $100 million-plus stock offering to make that happen.
Flexion's Zilretta won approval on Friday, with its official label winning praise from executives and analysts.
Sanofi is in talks to buy Flexion Therapeutics, a biotech with its lead product awaiting FDA approval, for more than $1 billion, according to a source close to the deal